Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of satralizumab in MOG antibody-associated disease
MOH_2023-06-26_012536Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started Jun 2023; status: recruiting.
02
Drugs
satralizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on MOH_2023-06-26_012536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-26_012536.